Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zentek Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's active prosecution is limited to a distinct examiner and a distinct art unit, indicating a focused interaction with the patent office. This concentration suggests that the company's current intellectual property efforts are centered on a specific technical area within biotechnology that is overseen by a single expert group.
MATTISON, LORI K is the busiest examiner for the portfolio, handling the 1 busiest examiner pending action. As the only examiner currently reviewing the company's pending work, their specific approach to the Biotechnology & Pharmaceuticals field will be the primary factor in the portfolio's immediate progress. Practitioners should analyze the examiner's historical data and art unit trends to craft a response that effectively addresses the pending office action.
With a distinct examiner involved, the administrative complexity of the portfolio is low, allowing for a very direct prosecution strategy. However, this also means that the company's current patenting goals in the Biotechnology & Pharmaceuticals area are entirely dependent on the resolution of this single matter. Successfully navigating the requirements of MATTISON, LORI K is essential for Zentek Ltd. to advance its patent position and clear its current pending workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATTISON, LORI K | 1 | 15.2% | +27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259010 | GRAPHENE OXIDE-CATIONIC SILVER NANOCOMPOSITES AND THEIR USE AS BROAD-SPECTRUM ANTIMICROBIAL AGENTS | MATTISON, LORI K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259010 | GRAPHENE OXIDE-CATIONIC SILVER NANOCOMPOSITES AND THEIR USE AS BROAD-SPECTRUM ANTIMICROBIAL AGENTS | MATTISON, LORI K | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18259010 | GRAPHENE OXIDE-CATIONIC SILVER NANOCOMPOSITES AND THEIR USE AS BROAD-SPECTRUM ANTIMICROBIAL AGENTS | MATTISON, LORI K | 1619 | §103Other | Non-Final OA | — | Pending | Jun 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZentek Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Lori K Mattison has the most, with 1 of Zentek Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.